Jeff Strovel, PhD

Dr. Strovel has more than 25 years of experience in research and development and a track record of leading successful drug development programs. He was the Head of Discovery Research at Avalon Pharmaceuticals, a publicly-traded biotechnology company, where he led multiple small molecule drug discovery and development programs and drove formation of strategic partnerships with large pharma and academia. Dr. Strovel was President and CSO of ConverGene Pharmaceuticals and led ConverGene as CEO from 2015 to 2017. During this time, Dr. Strovel established therapeutic programs in epigenetics and neurology and successfully out-licensed the company’s lead program. Dr. Strovel received his Bachelor of Science degree in Agriculture from West Virginia University and holds a PhD in Human Genetics from the University of Maryland at Baltimore. He received post-doctoral training as a clinical cytogenetics fellow at the National Cancer Institute at the National Institutes of Health in Bethesda